Reuters logo
BRIEF-Gilead announces Phase 2 results for GS-0976 in Nonalcoholic Steatohepatitis
2017年10月24日 / 下午2点35分 / 25 天前

BRIEF-Gilead announces Phase 2 results for GS-0976 in Nonalcoholic Steatohepatitis

Oct 24 (Reuters) - Gilead Sciences Inc:

* Announces Phase 2 results for GS-0976 in Nonalcoholic Steatohepatitis (NASH)

* In Phase 2 study, ‍oral ACC inhibitor led to significant reductions in measures of liver fat and fibrosis​

* In Phase 2 study, GS-0976 was well-tolerated; nausea, abdominal pain & diarrhea were most common adverse events​

* Differences between GS-0976 5 mg and placebo were not statistically significant​ Source text for Eikon: Further company coverage:

我们的标准:汤森路透“信任原则”
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below